One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood.v130.suppl_1.726.726
Copy DOI Journal: Blood |  Publication Date: Dec 7, 2017 |
 Citations: 25 |
Affiliation: The Ohio State University, University of California, Los Angeles, Agios Pharmaceuticals (United States), Memorial Sloan Kettering Cancer Center, University Hospital Ulm, Massachusetts General Hospital, City of Hope, University of Colorado Cancer Center, Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center, University of Chicago, The University of Texas MD Anderson Cancer Center, Vanderbilt University Medical CenterIvosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
